News tagged with bortezomib
Related topics: multiple myeloma
Bortezomib
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer
May 01, 2013 |
not rated yet |
0
